Tandem Diabetes Care (TNDM) Short-term Investments (2013 - 2026)

Tandem Diabetes Care has reported Short-term Investments for 14 years, with the latest figure at $390.9 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 24.08% year-over-year to $390.9 million; the trailing twelve-month figure through Mar 2026 stood at $390.9 million (up 24.08% YoY), and the FY2025 full-year result was $202.0 million, down 45.26% from the prior year.
• Short-term Investments for Q1 2026 stood at $390.9 million, up from $202.0 million in the prior quarter.
• The five-year high for Short-term Investments was $541.7 million in Q1 2022, with the low at $202.0 million in Q4 2025.
• Historically, Short-term Investments has averaged $387.1 million across 5 years, with a median of $404.7 million in 2024.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 37.96% — and 2025, when it slumped 46.46%.
• Tandem Diabetes Care's Short-term Investments stood at $444.4 million in 2022, then dropped by 7.95% to $409.0 million in 2023, then dropped by 9.77% to $369.1 million in 2024, then slumped by 45.26% to $202.0 million in 2025, then soared by 93.5% to $390.9 million in 2026.
• The last three Short-term Investments figures came in at $390.9 million (Q1 2026), $202.0 million (Q4 2025), and $227.2 million (Q3 2025), per Business Quant data.